Memorial Sloan Kettering signs deal with Abintus Bio

By The Science Advisory Board staff writers

November 17, 2021 -- Memorial Sloan Kettering Cancer Center has agreed to allow its next generation signaling technology 1XX to be used in Abintus Bio's in vivo CAR X products.

The products have the potential to improve outcomes for patients with hematologic malignancies and solid tumors while overcoming the challenges of ex vivo CAR technologies, according to Abintus Bio. Currently, 1XX CARs are under clinical evaluation in multiple cancers.

In vivo CAR X products aim to simultaneously target both adaptive and innate immune effector cells, including active T cells and NK cells, to produce an immune response against hematologic malignancies and solid tumors.

Abintus' initial products targeting hematologic and solid tumors are poised to enter clinical evaluation in early 2023.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here